---
title: "BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025"
description: "BioMarin Pharmaceutical Inc. anticipates a charge of approximately $221 million in Q3 2025 due to its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is expected to affect both GAAP a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260208070.md"
published_at: "2025-10-07T21:18:18.000Z"
---

# BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025

> BioMarin Pharmaceutical Inc. anticipates a charge of approximately $221 million in Q3 2025 due to its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is expected to affect both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. The figures are preliminary and subject to final financial statement procedures for the quarter ending September 30, 2025.

BioMarin Pharmaceutical Inc. expects to record acquired in-process research and development (IPR&D) charges of approximately $221 million in the third quarter of 2025 following its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is estimated to impact both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. BioMarin noted that these figures are preliminary and subject to final financial statement closing procedures for the quarter ended September 30, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001048477-25-000101), on October 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BMRN.US - BioMarin Pharma](https://longbridge.com/en/quote/BMRN.US.md)
- [INZY.US - Inozyme Pharma](https://longbridge.com/en/quote/INZY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 拜瑪林製藥未來收益展望 | 生物製藥公司（Biomarin Pharmaceutical，NASDAQ:BMRN）將於 2026 年 2 月 23 日公佈季度財報，分析師預計每股收益（EPS）為 0.41 美元。投資者希望能有積極的指引公告。上個季度，該公司每股收益未 | [Link](https://longbridge.com/en/news/276450980.md) |
| 拜瑪林製藥｜8-K：2025 財年營收 32 億美元超過預期 |  | [Link](https://longbridge.com/en/news/272322197.md) |
| 奧羅賓多製藥表示，税務部門要求公司歸還退税款 | Aurobindo Pharma 表示税務部門要求公司追回退款 | [Link](https://longbridge.com/en/news/276319861.md) |
| Madrigal 製藥｜8-K：2025 財年 Q4 營收 3.21 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| Mankind Pharma 表示，460 萬盧比的税務罰款已被撤銷 | Mankind Pharma Ltd：MANKIND PHARMA - 460 萬盧比的税務罰款被撤銷 | [Link](https://longbridge.com/en/news/276062229.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.